These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20509262)

  • 1. [Raltegravir: initially as effective as standard therapy].
    Warpakowski A
    MMW Fortschr Med; 2010 Apr; 152(17):49. PubMed ID: 20509262
    [No Abstract]   [Full Text] [Related]  

  • 2. [Integrase inhibitor: raltegravir also as first line therapy].
    MMW Fortschr Med; 2010 Apr; 152(17):48. PubMed ID: 20509261
    [No Abstract]   [Full Text] [Related]  

  • 3. Raltegravir treatment response in an HIV-2 infected patient: a case report.
    Garrett N; Xu L; Smit E; Ferns B; El-Gadi S; Anderson J
    AIDS; 2008 May; 22(9):1091-2. PubMed ID: 18520356
    [No Abstract]   [Full Text] [Related]  

  • 4. [Raltegravir as first integrase inhibitor in an HIV-infection].
    Papendorp SG; Brinkman K
    Ned Tijdschr Geneeskd; 2009 Jan; 153(5):166-7. PubMed ID: 19256240
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA notifications. Raltegravir indication extended for treatment-naive patients.
    AIDS Alert; 2009 Aug; 24(8):93. PubMed ID: 19705587
    [No Abstract]   [Full Text] [Related]  

  • 6. [Integrase inhibition--a new mode of action in HIV therapy].
    van Lunzen J; Degen O
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():64-7. PubMed ID: 19031567
    [No Abstract]   [Full Text] [Related]  

  • 7. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection.
    Rowley M
    Prog Med Chem; 2008; 46():1-28. PubMed ID: 18381123
    [No Abstract]   [Full Text] [Related]  

  • 11. [Integrase inhibition].
    Bogner JR
    MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
    [No Abstract]   [Full Text] [Related]  

  • 12. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
    Kravchenko AV
    Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of raltegravir in HIV/AIDS.
    Chaudhary MA; Elbasha EH; Kumar RN; Nathanson EC
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):627-39. PubMed ID: 22098278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
    Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
    AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
    [No Abstract]   [Full Text] [Related]  

  • 15. Raltegravir--beauty and the beast. Both the advantages and the limitations of this integrase inhibitor were evident this year.
    Albrecht H
    J Watch AIDS Clin Care; 2010 Jan; 22(1):4. PubMed ID: 20626067
    [No Abstract]   [Full Text] [Related]  

  • 16. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load.
    Papendorp SG; van den Berk GE
    AIDS; 2009 Mar; 23(6):739. PubMed ID: 19279447
    [No Abstract]   [Full Text] [Related]  

  • 17. Study supports use of Isentress for first line treatment.
    Proj Inf Perspect; 2008 Dec; (47):9. PubMed ID: 19227560
    [No Abstract]   [Full Text] [Related]  

  • 18. [Raltegravir - long lasting effectiveness, well tolerated and well combined].
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():30-1. PubMed ID: 23961651
    [No Abstract]   [Full Text] [Related]  

  • 19. Isentress gets another good grade.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):9. PubMed ID: 19043877
    [No Abstract]   [Full Text] [Related]  

  • 20. One-on-one with Joe Eron, M.D. An update on Isentress (raltegravir) data, including some unexpected results. Interview by Jeff Berry.
    Eron J
    Posit Aware; 2009; 20(3):46-7. PubMed ID: 19492451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.